These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21281505)

  • 1. Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.
    Smith LD; Tesoriero AA; Wong EM; Ramus SJ; O'Malley FP; Mulligan AM; Terry MB; Senie RT; Santella RM; John EM; Andrulis IL; Ozcelik H; Daly MB; Godwin AK; Buys SS; Fox S; Goldgar DE; Giles GG; Hopper JL; Southey MC
    Breast Cancer Res; 2011 Jan; 13(1):R14. PubMed ID: 21281505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.
    Malone KE; Daling JR; Thompson JD; O'Brien CA; Francisco LV; Ostrander EA
    JAMA; 1998 Mar; 279(12):922-9. PubMed ID: 9544766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 promoter deletions in young women with breast cancer and a strong family history: a population-based study.
    Smith LD; Tesoriero AA; Ramus SJ; Dite G; Royce SG; Giles GG; McCredie MR; Hopper JL; Southey MC
    Eur J Cancer; 2007 Mar; 43(5):823-7. PubMed ID: 17317153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
    Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
    Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
    J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
    Malone KE; Daling JR; Neal C; Suter NM; O'Brien C; Cushing-Haugen K; Jonasdottir TJ; Thompson JD; Ostrander EA
    Cancer; 2000 Mar; 88(6):1393-402. PubMed ID: 10717622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
    Southey MC; Ramus SJ; Dowty JG; Smith LD; Tesoriero AA; Wong EE; Dite GS; Jenkins MA; Byrnes GB; Winship I; Phillips KA; Giles GG; Hopper JL
    Br J Cancer; 2011 Mar; 104(6):903-9. PubMed ID: 21343941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
    Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
    Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.
    Neuhausen SL; Ozcelik H; Southey MC; John EM; Godwin AK; Chung W; Iriondo-Perez J; Miron A; Santella RM; Whittemore A; Andrulis IL; Buys SS; Daly MB; Hopper JL; Seminara D; Senie RT; Terry MB;
    Breast Cancer Res Treat; 2009 Jul; 116(2):379-86. PubMed ID: 18704680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Anglian Breast Cancer Study Group
    Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.
    Armes JE; Egan AJ; Southey MC; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer; 1998 Dec; 83(11):2335-45. PubMed ID: 9840533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
    Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
    BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas.
    Akbari MR; Donenberg T; Lunn J; Curling D; Turnquest T; Krill-Jackson E; Zhang S; Narod SA; Hurley J
    Clin Genet; 2014 Jan; 85(1):64-7. PubMed ID: 23458327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.